Search alternatives:
mean decrease » a decrease (Expand Search)
ng decrease » _ decrease (Expand Search), a decrease (Expand Search), we decrease (Expand Search)
nn decrease » _ decrease (Expand Search), a decrease (Expand Search), gy decreased (Expand Search)
p decrease » _ decrease (Expand Search), a decrease (Expand Search), _ decreased (Expand Search)
19 p » 19 _ (Expand Search)
Showing 61 - 80 results of 54,348 for search '(( 19 p decrease ) OR ( 5 ((ng decrease) OR (((nn decrease) OR (mean decrease)))) ))', query time: 0.86s Refine Results
  1. 61
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  2. 62
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  3. 63
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  4. 64
    Long-term anti-nucleocapsid response by baseline patient characteristics.

    Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  5. 65
    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90.

    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  6. 66
    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity.

    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  7. 67
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  8. 68
    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments).

    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  9. 69
    Baseline patient characteristics across neutralizing monoclonal antibody trials.

    Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  10. 70
    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies.

    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  11. 71
    Study Flow Diagram.

    Study Flow Diagram. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  12. 72
    CD11b and TLR-5 expression are decreased on CF macrophage membrane.

    CD11b and TLR-5 expression are decreased on CF macrophage membrane. by Karin Simonin-Le Jeune (464354)

    Published 2013
    Save to List
    Saved in:
  13. 73
    5-fluorouracil decreases rates of persistent and reappearing actinic keratoses: The VAKCC Trial

    5-fluorouracil decreases rates of persistent and reappearing actinic keratoses: The VAKCC Trial by Moniyka Sachar (9399032)

    Published 2020
    Save to List
    Saved in:
  14. 74
    Summary of findings table for the comparison remdesivir 10 days vs. placebo for hospitalized, severe COVID-19.

    Summary of findings table for the comparison remdesivir 10 days vs. placebo for hospitalized, severe COVID-19. by Alejandro Piscoya (782326)

    Published 2020
    Save to List
    Saved in:
  15. 75
    Mean value of ENSS and subscales.

    Mean value of ENSS and subscales. by Phu Dinh Vu (19429477)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  16. 76
    Fluoxetine decreases TOPFlash firefly luciferase reporter activity.

    Fluoxetine decreases TOPFlash firefly luciferase reporter activity. by Kentaro Miyamoto (123271)

    Published 2017
    Save to List
    Saved in:
  17. 77
    Rapamycin decreases phosphorylation of S6.

    Rapamycin decreases phosphorylation of S6. by Adam L. Hartman (308128)

    Published 2013
    Save to List
    Saved in:
  18. 78
    Summary of findings table for the comparison remdesivir 5 days vs. standard of care for hospitalized, moderate COVID-19.

    Summary of findings table for the comparison remdesivir 5 days vs. standard of care for hospitalized, moderate COVID-19. by Alejandro Piscoya (782326)

    Published 2020
    Save to List
    Saved in:
  19. 79
    Decreased mortality after ionising irradiation of p53<sup>-/-</sup> zebrafish embryos.

    Decreased mortality after ionising irradiation of p53<sup>-/-</sup> zebrafish embryos. by Seham Elabd (3540029)

    Published 2019
    Save to List
    Saved in:
  20. 80
    KCl treatment increases Elk1 SUMOylation and decreases katanin-p60 expression.

    KCl treatment increases Elk1 SUMOylation and decreases katanin-p60 expression. by Ece Selçuk (436963)

    Published 2013
    Save to List
    Saved in:

Search Tools: